India Tops China As Preferred Site Of Outsourced Clinical Trials
This article was originally published in PharmAsia News
India has surpassed China as the country preferred by foreign drug makers for conducting clinical trials. India's Planning Commission says the country received 139 new trials over a recent period when China received 98. The commission said the outsourced trials are worth about $300 million to the country and the amount is expected to grow to as much as $2 billion within two years. The same report noted, however, that India is short 30,000 to 50,000 research personnel needed to carry out the trials. (Click here for more
You may also be interested in...
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Early Research Suggests Wearables Can Spot Early Signs Of COVID-19; Fitbit Receives $2.5m Army Award
A consortium of researchers, including Fitbit, are developing algorithms to spot COVID-19 before people become ill.